- Home
- MYGN vs MRX Comparison
MYGN vs MRX Comparison
Compare MYGN & MRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- MRX
- Stock Information
- Founded
- MYGN 1991
- MRX 2005
- Country
- MYGN United States
- MRX United Kingdom
- Employees
- MYGN N/A
- MRX N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MRX
- Sector
- MYGN Health Care
- MRX
- Exchange
- MYGN Nasdaq
- MRX NYSE
- Market Cap
- MYGN 2.0B
- MRX 2.2B
- IPO Year
- MYGN 1995
- MRX 2024
- Fundamental
- Price
- MYGN $12.39
- MRX $33.75
- Analyst Decision
- MYGN Hold
- MRX Strong Buy
- Analyst Count
- MYGN 12
- MRX 8
- Target Price
- MYGN $23.92
- MRX $33.25
- AVG Volume (30 Days)
- MYGN 1.0M
- MRX 316.7K
- Earning Date
- MYGN 02-25-2025
- MRX 02-25-2025
- Dividend Yield
- MYGN N/A
- MRX 0.83%
- EPS Growth
- MYGN N/A
- MRX 2.80
- EPS
- MYGN N/A
- MRX 2.51
- Revenue
- MYGN $823,600,000.00
- MRX $1,539,450,000.00
- Revenue This Year
- MYGN $13.82
- MRX N/A
- Revenue Next Year
- MYGN $4.59
- MRX $7.14
- P/E Ratio
- MYGN N/A
- MRX $13.43
- Revenue Growth
- MYGN 12.15
- MRX N/A
- 52 Week Low
- MYGN $12.17
- MRX $18.13
- 52 Week High
- MYGN $29.30
- MRX $34.19
- Technical
- Relative Strength Index (RSI)
- MYGN 29.80
- MRX N/A
- Support Level
- MYGN $12.17
- MRX N/A
- Resistance Level
- MYGN $15.08
- MRX N/A
- Average True Range (ATR)
- MYGN 0.79
- MRX 0.00
- MACD
- MYGN -0.01
- MRX 0.00
- Stochastic Oscillator
- MYGN 7.56
- MRX 0.00
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About MRX MAREX GROUP PLC
Marex Group PLC is a company that offers a diversified global financial services platform providing essential liquidity, market access and infrastructure services to clients across energy, commodities and financial markets. It provides critical services to the clients by connecting them to global exchanges and providing a range of execution and hedging services across a range of its asset and products. They operate in a large and fragmented market with significant infrastructure requirements and regulatory and technological complexity, resulting in high barriers to entry.